Ticagrelor Treatment Associated With Increased Coronary Flow Reserve in Survivors of MI
An observational cross-sectional study of high-risk survivors of MI found higher CFR in ticagrelor participants suggesting pleiotropic effects of ticagrelor with benefits in combination with platelet inhibition.
It is already known that the pleiotropic action of ticagrelor, in addition to platelet inhibition, improves endothelial function in coronary artery disease patients. These positive effects are adenosine mediated.
Considering this background, the study investigated the association of ticagrelor therapy and coronary artery flow reserve in survivors of myocardial infarction (MI) patients.
This was an open substudy of PROFLOW. Using transthoracic Doppler echocardiography, researchers measured Coronary flow reserve (CFR) non-invasively in the left anterior descending artery. Coronary flow velocity was measured at rest and maximal flow after induction of hyperaemia by intravenous infusion of adenosine at 140 μg/kg/min.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.